Selected research
Market Analysis & Forecast
Global Nano Antibodies Market Analysis and Forecast 2026-2032
Market perspective
The global Nano Antibodies market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Nano Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Nano Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Nano Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Nano Antibodies is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Nano Antibodies include Absolute Antibody, Alpalife (Shenzhen kangti Co., Ltd.), Alphamab Oncology, Beroni Group, ChromoTek GmbH, Cusabio Technology LLC., DiosCURE Therapeutics SE, ExeVir Bio BV and Genscript, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Nano Antibodies, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Nano Antibodies, also provides the revenue of main regions and countries. Of the upcoming market potential for Nano Antibodies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nano Antibodies revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nano Antibodies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nano Antibodies revenue, projected growth trends, production technology, application and end-user industry.
Nano Antibodies Segment by Company
Absolute Antibody
Alpalife (Shenzhen kangti Co., Ltd.)
Alphamab Oncology
Beroni Group
ChromoTek GmbH
Cusabio Technology LLC.
DiosCURE Therapeutics SE
ExeVir Bio BV
Genscript
PerkinElmer Inc. (BioLegend, Inc.)
Sensei Biotherapeutics, Inc.
Taisho Pharmaceutical Holdings
Merck KGaA
Novartis AG
Thermo Fisher Scientific Inc.
Sanofi (Ablynx)
Nano Antibodies Segment by Type
Fusion Nanobody
Multivalent and multispecific Nanobodies
Monovalent Nanobody
Nano Antibodies Segment by Application
Tumor targeted therapy
Circulatory disease
Disease detection in vitro
Non-invasive diagnosis in vivo
Nervous system disease
Infectious disease
Other
Nano Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nano Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Nano Antibodies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Nano Antibodies company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nano Antibodies revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fusion Nanobody
- Multivalent and multispecific Nanobodies
- Monovalent Nanobody
Applications
- Tumor targeted therapy
- Circulatory disease
- Disease detection in vitro
- Non-invasive diagnosis in vivo
- Nervous system disease
- Infectious disease
- Other
Companies covered
- Absolute Antibody
- Alpalife (Shenzhen kangti Co., Ltd.)
- Alphamab Oncology
- Beroni Group
- ChromoTek GmbH
- Cusabio Technology LLC.
- DiosCURE Therapeutics SE
- ExeVir Bio BV
- Genscript
- PerkinElmer Inc. (BioLegend, Inc.)
- Sensei Biotherapeutics, Inc.
- Taisho Pharmaceutical Holdings
- Merck KGaA
- Novartis AG
- Thermo Fisher Scientific Inc.
- Sanofi (Ablynx)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Nano Antibodies Market by Type
- 1.2.1 Global Nano Antibodies Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Fusion Nanobody
- 1.2.3 Multivalent and multispecific Nanobodies
- 1.2.4 Monovalent Nanobody
- 1.3 Nano Antibodies Market by Application
- 1.3.1 Global Nano Antibodies Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Tumor targeted therapy
- 1.3.3 Circulatory disease
- 1.3.4 Disease detection in vitro
- 1.3.5 Non-invasive diagnosis in vivo
- 1.3.6 Nervous system disease
- 1.3.7 Infectious disease
- 1.3.8 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Nano Antibodies Market Dynamics
- 2.1 Nano Antibodies Industry Trends
- 2.2 Nano Antibodies Industry Drivers
- 2.3 Nano Antibodies Industry Opportunities and Challenges
- 2.4 Nano Antibodies Industry Restraints
3 Global Growth Perspective
- 3.1 Global Nano Antibodies Market Perspective (2021-2032)
- 3.2 Global Nano Antibodies Growth Trends by Region
- 3.2.1 Global Nano Antibodies Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Nano Antibodies Market Size by Region (2021-2026)
- 3.2.3 Global Nano Antibodies Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Nano Antibodies Revenue by Players
- 4.1.1 Global Nano Antibodies Revenue by Players (2021-2026)
- 4.1.2 Global Nano Antibodies Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Nano Antibodies Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Nano Antibodies Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Nano Antibodies Key Players Headquarters & Area Served
- 4.4 Global Nano Antibodies Players, Product Type & Application
- 4.5 Global Nano Antibodies Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Nano Antibodies Market CR5 and HHI
- 4.6.3 2025 Nano Antibodies Tier 1, Tier 2, and Tier 3
5 Nano Antibodies Market Size by Type
- 5.1 Global Nano Antibodies Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Nano Antibodies Revenue by Type (2021-2032)
- 5.3 Global Nano Antibodies Revenue Market Share by Type (2021-2032)
6 Nano Antibodies Market Size by Application
- 6.1 Global Nano Antibodies Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Nano Antibodies Revenue by Application (2021-2032)
- 6.3 Global Nano Antibodies Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Absolute Antibody
- 7.1.1 Absolute Antibody Company Information
- 7.1.2 Absolute Antibody Business Overview
- 7.1.3 Absolute Antibody Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.1.4 Absolute Antibody Nano Antibodies Product Portfolio
- 7.1.5 Absolute Antibody Recent Developments
- 7.2 Alpalife (Shenzhen kangti Co., Ltd.)
- 7.2.1 Alpalife (Shenzhen kangti Co., Ltd.) Company Information
- 7.2.2 Alpalife (Shenzhen kangti Co., Ltd.) Business Overview
- 7.2.3 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.2.4 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Product Portfolio
- 7.2.5 Alpalife (Shenzhen kangti Co., Ltd.) Recent Developments
- 7.3 Alphamab Oncology
- 7.3.1 Alphamab Oncology Company Information
- 7.3.2 Alphamab Oncology Business Overview
- 7.3.3 Alphamab Oncology Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.3.4 Alphamab Oncology Nano Antibodies Product Portfolio
- 7.3.5 Alphamab Oncology Recent Developments
- 7.4 Beroni Group
- 7.4.1 Beroni Group Company Information
- 7.4.2 Beroni Group Business Overview
- 7.4.3 Beroni Group Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.4.4 Beroni Group Nano Antibodies Product Portfolio
- 7.4.5 Beroni Group Recent Developments
- 7.5 ChromoTek GmbH
- 7.5.1 ChromoTek GmbH Company Information
- 7.5.2 ChromoTek GmbH Business Overview
- 7.5.3 ChromoTek GmbH Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.5.4 ChromoTek GmbH Nano Antibodies Product Portfolio
- 7.5.5 ChromoTek GmbH Recent Developments
- 7.6 Cusabio Technology LLC.
- 7.6.1 Cusabio Technology LLC. Company Information
- 7.6.2 Cusabio Technology LLC. Business Overview
- 7.6.3 Cusabio Technology LLC. Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.6.4 Cusabio Technology LLC. Nano Antibodies Product Portfolio
- 7.6.5 Cusabio Technology LLC. Recent Developments
- 7.7 DiosCURE Therapeutics SE
- 7.7.1 DiosCURE Therapeutics SE Company Information
- 7.7.2 DiosCURE Therapeutics SE Business Overview
- 7.7.3 DiosCURE Therapeutics SE Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.7.4 DiosCURE Therapeutics SE Nano Antibodies Product Portfolio
- 7.7.5 DiosCURE Therapeutics SE Recent Developments
- 7.8 ExeVir Bio BV
- 7.8.1 ExeVir Bio BV Company Information
- 7.8.2 ExeVir Bio BV Business Overview
- 7.8.3 ExeVir Bio BV Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.8.4 ExeVir Bio BV Nano Antibodies Product Portfolio
- 7.8.5 ExeVir Bio BV Recent Developments
- 7.9 Genscript
- 7.9.1 Genscript Company Information
- 7.9.2 Genscript Business Overview
- 7.9.3 Genscript Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.9.4 Genscript Nano Antibodies Product Portfolio
- 7.9.5 Genscript Recent Developments
- 7.10 PerkinElmer Inc. (BioLegend, Inc.)
- 7.10.1 PerkinElmer Inc. (BioLegend, Inc.) Company Information
- 7.10.2 PerkinElmer Inc. (BioLegend, Inc.) Business Overview
- 7.10.3 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.10.4 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Product Portfolio
- 7.10.5 PerkinElmer Inc. (BioLegend, Inc.) Recent Developments
- 7.11 Sensei Biotherapeutics, Inc.
- 7.11.1 Sensei Biotherapeutics, Inc. Company Information
- 7.11.2 Sensei Biotherapeutics, Inc. Business Overview
- 7.11.3 Sensei Biotherapeutics, Inc. Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.11.4 Sensei Biotherapeutics, Inc. Nano Antibodies Product Portfolio
- 7.11.5 Sensei Biotherapeutics, Inc. Recent Developments
- 7.12 Taisho Pharmaceutical Holdings
- 7.12.1 Taisho Pharmaceutical Holdings Company Information
- 7.12.2 Taisho Pharmaceutical Holdings Business Overview
- 7.12.3 Taisho Pharmaceutical Holdings Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.12.4 Taisho Pharmaceutical Holdings Nano Antibodies Product Portfolio
- 7.12.5 Taisho Pharmaceutical Holdings Recent Developments
- 7.13 Merck KGaA
- 7.13.1 Merck KGaA Company Information
- 7.13.2 Merck KGaA Business Overview
- 7.13.3 Merck KGaA Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.13.4 Merck KGaA Nano Antibodies Product Portfolio
- 7.13.5 Merck KGaA Recent Developments
- 7.14 Novartis AG
- 7.14.1 Novartis AG Company Information
- 7.14.2 Novartis AG Business Overview
- 7.14.3 Novartis AG Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.14.4 Novartis AG Nano Antibodies Product Portfolio
- 7.14.5 Novartis AG Recent Developments
- 7.15 Thermo Fisher Scientific Inc.
- 7.15.1 Thermo Fisher Scientific Inc. Company Information
- 7.15.2 Thermo Fisher Scientific Inc. Business Overview
- 7.15.3 Thermo Fisher Scientific Inc. Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.15.4 Thermo Fisher Scientific Inc. Nano Antibodies Product Portfolio
- 7.15.5 Thermo Fisher Scientific Inc. Recent Developments
- 7.16 Sanofi (Ablynx)
- 7.16.1 Sanofi (Ablynx) Company Information
- 7.16.2 Sanofi (Ablynx) Business Overview
- 7.16.3 Sanofi (Ablynx) Nano Antibodies Revenue and Gross Margin (2021-2026)
- 7.16.4 Sanofi (Ablynx) Nano Antibodies Product Portfolio
- 7.16.5 Sanofi (Ablynx) Recent Developments
8 North America
- 8.1 North America Nano Antibodies Revenue (2021-2032)
- 8.2 North America Nano Antibodies Revenue by Type (2021-2032)
- 8.2.1 North America Nano Antibodies Revenue by Type (2021-2026)
- 8.2.2 North America Nano Antibodies Revenue by Type (2027-2032)
- 8.3 North America Nano Antibodies Revenue Share by Type (2021-2032)
- 8.4 North America Nano Antibodies Revenue by Application (2021-2032)
- 8.4.1 North America Nano Antibodies Revenue by Application (2021-2026)
- 8.4.2 North America Nano Antibodies Revenue by Application (2027-2032)
- 8.5 North America Nano Antibodies Revenue Share by Application (2021-2032)
- 8.6 North America Nano Antibodies Revenue by Country
- 8.6.1 North America Nano Antibodies Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Nano Antibodies Revenue by Country (2021-2026)
- 8.6.3 North America Nano Antibodies Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Nano Antibodies Revenue (2021-2032)
- 9.2 Europe Nano Antibodies Revenue by Type (2021-2032)
- 9.2.1 Europe Nano Antibodies Revenue by Type (2021-2026)
- 9.2.2 Europe Nano Antibodies Revenue by Type (2027-2032)
- 9.3 Europe Nano Antibodies Revenue Share by Type (2021-2032)
- 9.4 Europe Nano Antibodies Revenue by Application (2021-2032)
- 9.4.1 Europe Nano Antibodies Revenue by Application (2021-2026)
- 9.4.2 Europe Nano Antibodies Revenue by Application (2027-2032)
- 9.5 Europe Nano Antibodies Revenue Share by Application (2021-2032)
- 9.6 Europe Nano Antibodies Revenue by Country
- 9.6.1 Europe Nano Antibodies Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Nano Antibodies Revenue by Country (2021-2026)
- 9.6.3 Europe Nano Antibodies Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Nano Antibodies Revenue (2021-2032)
- 10.2 China Nano Antibodies Revenue by Type (2021-2032)
- 10.2.1 China Nano Antibodies Revenue by Type (2021-2026)
- 10.2.2 China Nano Antibodies Revenue by Type (2027-2032)
- 10.3 China Nano Antibodies Revenue Share by Type (2021-2032)
- 10.4 China Nano Antibodies Revenue by Application (2021-2032)
- 10.4.1 China Nano Antibodies Revenue by Application (2021-2026)
- 10.4.2 China Nano Antibodies Revenue by Application (2027-2032)
- 10.5 China Nano Antibodies Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Nano Antibodies Revenue (2021-2032)
- 11.2 Asia Nano Antibodies Revenue by Type (2021-2032)
- 11.2.1 Asia Nano Antibodies Revenue by Type (2021-2026)
- 11.2.2 Asia Nano Antibodies Revenue by Type (2027-2032)
- 11.3 Asia Nano Antibodies Revenue Share by Type (2021-2032)
- 11.4 Asia Nano Antibodies Revenue by Application (2021-2032)
- 11.4.1 Asia Nano Antibodies Revenue by Application (2021-2026)
- 11.4.2 Asia Nano Antibodies Revenue by Application (2027-2032)
- 11.5 Asia Nano Antibodies Revenue Share by Application (2021-2032)
- 11.6 Asia Nano Antibodies Revenue by Country
- 11.6.1 Asia Nano Antibodies Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Nano Antibodies Revenue by Country (2021-2026)
- 11.6.3 Asia Nano Antibodies Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Nano Antibodies Revenue (2021-2032)
- 12.2 SAMEA Nano Antibodies Revenue by Type (2021-2032)
- 12.2.1 SAMEA Nano Antibodies Revenue by Type (2021-2026)
- 12.2.2 SAMEA Nano Antibodies Revenue by Type (2027-2032)
- 12.3 SAMEA Nano Antibodies Revenue Share by Type (2021-2032)
- 12.4 SAMEA Nano Antibodies Revenue by Application (2021-2032)
- 12.4.1 SAMEA Nano Antibodies Revenue by Application (2021-2026)
- 12.4.2 SAMEA Nano Antibodies Revenue by Application (2027-2032)
- 12.5 SAMEA Nano Antibodies Revenue Share by Application (2021-2032)
- 12.6 SAMEA Nano Antibodies Revenue by Country
- 12.6.1 SAMEA Nano Antibodies Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Nano Antibodies Revenue by Country (2021-2026)
- 12.6.3 SAMEA Nano Antibodies Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst